Skip to content

US · HRTX · BIOTECHNOLOGY

Heron Therapeutics, Inc. (HRTX) intrinsic value and stock valuation

$0.25as of 2026-11-21 · Mkt cap 95.55M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Heron Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values HRTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HRTX’s statements →

Heron Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cary, NC 27511 herontx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$154.9M+11.8% 5y CAGRd
20112025
Net income
-$-20.2M
20112025
Free cash flow
-$-27.91M
20112025
Total equity
$14.3M-42.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$154.9M$144.3M$127M$107.7M$86.4M
Operating income-$-2.54M-$-11.53M-$-110.61M-$-174.66M-$-217.83M
Net income-$-20.2M-$-13.58M-$-110.56M-$-182.02M-$-220.68M
EPSd-$-121.17K-$-89.08K-$-800.41K-$-1.67M-$-2.24M
Operating cash flow-$-27.59M-$-22.53M-$-58.79M-$-146.91M-$-203.35M
Capital expenditure-$-320K-$-1.71M-$-1.54M-$-1.82M-$-3.02M
Free cash flow-$-27.91M-$-24.23M-$-60.33M-$-148.74M-$-206.38M
Total assets$255.9M$233.2M$222.5M$251M$305.7M
Total debt$140.6M$177.8M$179.6M$157.5M$159.5M
Net debt$112M$152M$151M$142.1M$69M
Total equity$14.3M-$-33.65M-$-33.97M$13.6M$77.6M
Cash and short-term investments$46.6M$59.3M$80.4M$84.9M$157.6M
Income statement
20252024202320222021
Revenue$154.9M$144.3M$127M$107.7M$86.4M
Cost of revenue$41.4M$38.7M$65.1M$54.9M$46M
Gross profit$113.6M$105.6M$61.9M$52.8M$40.3M
Research and development expenses$12.4M$16.7M$39.1M$82.7M$130.8M
Selling, general and administrative expenses$103.7M$100.5M$119.8M$144.8M$127.3M
Other expenses$0.00$0.00$13.6M$0.00$0.00
Operating expenses$116.1M$117.2M$172.6M$227.5M$258.2M
Cost and expenses$157.4M$155.8M$237.7M$282.3M$304.2M
Interest income$0.00$3.55M$3.36M$1.64M$430K
Interest expense$0.00$6.03M$3.87M$2.47M$2.41M
Depreciation and amortization$2.31M$2.49M$2.9M$2.89M$3.02M
Ebitda-$-17.88M-$-5.06M-$-103.79M-$-176.66M-$-215.25M
Operating income-$-2.54M-$-11.53M-$-110.61M-$-174.66M-$-217.83M
Total other income/expenses, net-$-17.66M-$-2.05M$60K-$-7.37M-$-2.85M
Income before tax-$-20.2M-$-13.58M-$-110.56M-$-182.02M-$-220.68M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.2M-$-13.58M-$-110.56M-$-182.02M-$-220.68M
Weighted average shares outstanding$166.7M$152.5M$138.1M$109M$98.5M
Weighted average diluted shares outstanding$166.7M$152.5M$138.1M$109M$98.5M
Balance sheet
20252024202320222021
Cash and short-term investments$46.6M$59.3M$80.4M$84.9M$157.6M
Net receivables$89.6M$78.9M$60.1M$52.1M$35.5M
Inventory$92.8M$53.2M$42.1M$54.6M$48.4M
Total current assets$238.1M$209M$188.8M$205.4M$254.4M
Property, plant and equipment, net$12.4M$17.7M$25.6M$29.8M$33.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$17.8M$24.1M$33.7M$45.5M$51.3M
Total assets$255.9M$233.2M$222.5M$251M$305.7M
Accounts payable$8.99M$11.7M$3.8M$3.59M$3.87M
Short-term debt$0.00$3.04M$3.08M$2.69M$2.42M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$96.1M$91.5M$79.7M$82.4M$71.1M
Long-term debt$140.6M$174.7M$176.6M$154.8M$157.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$145.5M$175.3M$176.8M$155M$157.1M
Capital lease obligations$0.00$3.04M$5.88M$8.19M$10.4M
Total liabilities$241.5M$266.8M$256.5M$237.4M$228.1M
Common stock$1.88M$1.52M$1.5M$1.19M$1.02M
Retained earnings-$-1.94B-$-1.92B-$-1.91B-$-1.8B-$-1.61B
Accumulated other comprehensive income (loss)$0.00$10K$10K-$-20K-$-10K
Total equity$14.3M-$-33.65M-$-33.97M$13.6M$77.6M
Total investments$18M$33.5M$51.7M$69.5M$67M
Total debt$140.6M$177.8M$179.6M$157.5M$159.5M
Net debt$112M$152M$151M$142.1M$69M
Cash flow statement
20252024202320222021
Net income-$-20.2M-$-13.58M-$-110.56M-$-182.02M-$-220.68M
Depreciation and amortization$2.31M$2.49M$2.9M$2.89M$3.02M
Stock-based compensation$10.3M$13M$32.9M$43M$46.9M
Change in working capital-$-31.88M-$-27.6M$16.8M-$-10.51M-$-35.08M
Accounts receivable-$-10.71M-$-18.74M-$-8.09M-$-16.55M$6.35M
Inventory-$-31.05M-$-11.05M$12.5M-$-6.19M-$-6.48M
Accounts payable-$-2.71M$8.47M$10K-$-580K$3.28M
Net cash provided by operating activities-$-27.59M-$-22.53M-$-58.79M-$-146.91M-$-203.35M
Investments in property, plant and equipment-$-320K-$-1.71M-$-1.54M-$-1.82M-$-3.02M
Acquisitions, net$0.00$30K$10K$230K$30K
Net cash used for investing activities$16M$18.7M$18M-$-3.32M$32.7M
Common stock issued$19.3M$940K$29.8M$75.1M$7.07M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.4M$940K$54.1M$75.1M$156M
Net change in cash$2.85M-$-2.88M$13.3M-$-75.18M-$-14.6M
Cash at end of period$28.7M$25.8M$28.7M$15.4M$90.5M
Operating cash flow-$-27.59M-$-22.53M-$-58.79M-$-146.91M-$-203.35M
Capital expenditure-$-320K-$-1.71M-$-1.54M-$-1.82M-$-3.02M
Free cash flow-$-27.91M-$-24.23M-$-60.33M-$-148.74M-$-206.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Heron Therapeutics, Inc.

        Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.

        CEO
        Craig Alexander Collard
        Employees
        128
        Beta
        1.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Heron Therapeutics, Inc. (HRTX)?

        InvestorsCraft does not currently publish an intrinsic value for HRTX. How the IC value is calculated.

        Is HRTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for HRTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.